Larimar Therapeutics
Develops nomlabofusp to deliver frataxin in Friedreich's ataxia.
Something off on this page? Send us feedback.
Profile
Develops nomlabofusp, a subcutaneous recombinant fusion protein intended to deliver frataxin to mitochondria in Friedreich's ataxia. Operates as a U.S.-based clinical-stage biotech with one development segment and no approved commercial product in the context sources.
Built around nomlabofusp, a subcutaneous recombinant fusion protein intended to deliver frataxin to mitochondria in Friedreich's ataxia patients. The program came from Chondrial's CTI-1601 work and remains the named lead asset in Larimar's pipeline.
Runs as a U.S.-based clinical-stage biotechnology company with one reportable segment for clinical and preclinical product development. Pipeline materials describe a CPP intracellular delivery platform, but context sources identify no separate marketed product or named second clinical candidate.
Execution centers on regulatory development: FDA removed a partial clinical hold, later granted Breakthrough Therapy Designation, and Larimar submitted the first module of a rolling BLA. The business depends on nomlabofusp development and regulatory review rather than commercial product sales.
Company facts
Key statistics
Year to date +15.3% · Average volume (30d) 1.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 5, 2026 | Wedbush | Reiterate | Outperform | $12 | $11 |
| Jun 30, 2026 | Robert W. Baird | Target | $7 | $5 | |
| Mar 3, 2026 | Wedbush | Reiterate | Outperform | $22 | $12 |
| Sep 30, 2025 | Robert W. Baird | Target | $7 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | −$0.38 | −$0.30 | +21.4% | — | — | — | +3.27% |
| May 14, 2026Q1 FY26 | −$0.53 | −$0.31 | +41.5% | — | — | — | −7.97% |
| Mar 19, 2026Q4 FY25 | −$0.44 | −$0.73 | −65.9% | — | — | — | +0.45% |
| Nov 5, 2025Q3 FY25 | −$0.39 | −$0.61 | −56.4% | — | — | — | +7.76% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$31.2M | −$27.8M | −$49.5M | −$64.0M | −$31.1M | −$34.4M | |
| Net income | −$29.3M | −$26.2M | −$47.7M | −$62.5M | −$29.6M | −$32.8M | |
| Diluted EPS | −$0.46 | −$0.41 | −$0.61 | −$0.73 | −$0.35 | −$0.30 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $156.3M · Total debt $5.0M · Total assets $165.3M · Shareholders' equity $127.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 103.88M · Float 59.94M · 57.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 35.61M | 34.28% | 13F | May 15, 2026 |
| Blue Owl Capital Holdings LP | 10.74M | 9.99% | 13G | May 14, 2026 |
| James E. Flynn · director, 10 percent owner, other: * Director by Deputization | 6.21M | 5.98% | Form 4 | Mar 2, 2026 |
| BlackRock, Inc. | 3.75M | 3.61% | 13F | May 13, 2026 |
| Millennium Management LLC | 3.63M | 3.49% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 6, 2026 | Thomas Edward Hamilton | director | +50,000 | $3.34 |
| Feb 27, 2026 | Jeffrey W. Sherman | director | +5,000 | $5.00 |
| Feb 27, 2026 | Frank E. Thomas | director | +5,000 | $5.00 |
| Feb 27, 2026 | Thomas Edward Hamilton | director | +100,000 | $5.00 |
| Feb 27, 2026 | James E. Flynn | director, 10 percent owner, other: * Director by Deputization | +5,000,000 | $5.00 |
Peers
- Biogen
Approved FA therapy anchor through Skyclarys
- PTC Therapeutics
Registration-stage FA small molecule vatiquinone
- Lexeo Therapeutics
FA cardiomyopathy gene therapy with LX2006
- Design Therapeutics
Frataxin-expression program with DT-216P2
- Solid Biosciences
Early FA dual-route gene therapy SGT-212
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Larimar Therapeutics | $4.09 | +2.25% | $416.6M | — | — | — | — |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| PTC Therapeutics | $70.59 | +0.73% | $5.85B | — | 58.0 | 5.8 | +101.6% |
| Lexeo Therapeutics | $4.77 | −1.95% | $381.6M | — | — | — | — |
| Design Therapeutics | $15.11 | +0.07% | $943.7M | — | — | — | — |
| Solid Biosciences | $9.77 | −0.10% | $961.9M | — | — | — | — |
| Median | 38.7 | 37.2 | 4.5 | +52.5% |